HER2-E-CART cells

PreclinicalCell therapy

HER2-E-CART cells is one of 7 biologic programs targeting Chimeric Antigen Receptor T-cell. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chimeric Antigen Receptor T-CellUnknown status

Chimeric Antigen Receptor T-CellPreclinical

Unknown status

Competition

Competitive Landscape

7 competitors in Chimeric Antigen Receptor T-Cell

#DrugCompanyPhaseTrials

Immunoglobulin

Sanofi

Phase 3

1 2

Copiktra

SSecuraBio

Phase 1

1 3

FOLFIRI

Amgen

Phase 1

1 4

FOLFOX

AstraZeneca

Phase 1

1 5

Cd19x22 CAR T

UUniversity of Colorado, Denver

Phase 1

1 6

CYAD-101

CCelyad Oncology SA

Phase 1

1 7

HER2-E-CART cells

Ssu haichuan

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chimeric Antigen Receptor T-cell1 trial

A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors

Unknown status·Ssu haichuan·N/A·NCT05745454·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HER2-E-CART cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HER2-E-CART cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HER2-E-CART cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — su haichuan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: Ssu haichuan

HER2-E-CART cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chimeric Antigen Receptor T-cell1 trial

References

Drug Info

Quick Facts

Related News